Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies.
about
Mechanisms of STAT protein activation by oncogenic KIT mutants in neoplastic mast cellsMast cell homeostasis and the JAK-STAT pathwayRoles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistanceChronic myeloid leukemia: reminiscences and dreamsRegulators of Actin Dynamics in Gastrointestinal Tract TumorsLoss of function of TET2 cooperates with constitutively active KIT in murine and human models of mastocytosisStructure of an Unprecedented G-Quadruplex Scaffold in the Human c-kit PromoterSolution structures of all parallel-stranded monomeric and dimeric G-quadruplex scaffolds of the human c-kit2 promoterTreating adults with acute lymphocytic leukemia: new pharmacotherapy options.Natural products active in aberrant c-Kit signaling.New dosing schedules of dasatinib for CML and adverse event managementImatinib and nilotinib reverse multidrug resistance in cancer cells by inhibiting the efflux activity of the MRP7 (ABCC10).Anomalous constitutive Src kinase activity promotes B lymphoma survival and growth.Antitumor activity of targeting SRC kinases in endothelial and myeloid cell compartments of the tumor microenvironmentGene expression signatures and response to imatinib mesylate in gastrointestinal stromal tumor.Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and JAK inhibitors.Bortezomib induces apoptosis in primitive chronic myeloid leukemia cells including LTC-IC and NOD/SCID repopulating cells.Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML.A phase II study of dasatinib in patients with chemosensitive relapsed small cell lung cancer (Cancer and Leukemia Group B 30602).NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors.BDNF released during neuropathic pain potentiates NMDA receptors in primary afferent terminalsMotesanib inhibits Kit mutations associated with gastrointestinal stromal tumors.Combined BRAF(V600E)- and SRC-inhibition induces apoptosis, evokes an immune response and reduces tumor growth in an immunocompetent orthotopic mouse model of anaplastic thyroid cancer.Dasatinib impairs long-term expansion of leukemic progenitors in a subset of acute myeloid leukemia cases.Novel dual Src/Abl inhibitors for hematologic and solid malignancies.Unique effects of KIT D816V in BaF3 cells: induction of cluster formation, histamine synthesis, and early mast cell differentiation antigens.ACK1 tyrosine kinase interacts with histone demethylase KDM3A to regulate the mammary tumor oncogene HOXA1Dasatinib inhibits the growth of molecularly heterogeneous myeloid leukemias.Modulating the stem cell niche for tissue regeneration.C-KIT mutation cooperates with full-length AML1-ETO to induce acute myeloid leukemia in miceAcute myeloid leukemia with the 8q22;21q22 translocation: secondary mutational events and alternative t(8;21) transcripts.Recent advances in the understanding of mastocytosis: the role of KIT mutations.Protein kinase inhibitors substantially improve the physical detection of T-cells with peptide-MHC tetramersTargeted inhibition of kinases in cancer therapySelecting tyrosine kinase inhibitors for gastrointestinal stromal tumor with secondary KIT activation-loop domain mutationsFlumatinib, a selective inhibitor of BCR-ABL/PDGFR/KIT, effectively overcomes drug resistance of certain KIT mutants.Attenuated expression of apoptosis stimulating protein of p53-2 (ASPP2) in human acute leukemia is associated with therapy failureDasatinib targets B-lineage cells but does not provide an effective therapy for myeloproliferative disease in c-Cbl RING finger mutant mice.Antitumor effect of the tyrosine kinase inhibitor nilotinib on gastrointestinal stromal tumor (GIST) and imatinib-resistant GIST cellsBiology of childhood germ cell tumours, focussing on the significance of microRNAs.
P2860
Q24313261-7BA6BF81-F225-4326-8BAE-3CA346225E73Q24632515-395827A5-0403-450D-B450-42EF20495727Q24645668-34A37ECD-243E-451A-B9F5-F5B7AB474142Q26748769-3067974C-0FF7-4162-B5DD-564276D99D83Q26783246-EC087012-5833-4904-BF76-510192F20A5EQ27334940-44AF6857-22B1-46F4-A8B1-EB7E89119615Q27644075-1F0C5E8E-6793-4FB9-AD37-2F8AD0E1B5D3Q27662546-C197D2E1-D59E-4887-80DE-9E0F6EB027A7Q30243925-522505FB-BA88-430F-A872-1DEB3F9ADDC0Q33286316-B4E2F762-2D25-45B7-8698-6DC3A2C2AA5FQ33383407-58E6AE5B-AB3C-40A5-8A1E-207C99A19F27Q33511437-5A4804C6-4A98-40BA-9161-900BAC72330DQ33623874-695C1934-21DD-49FB-B14C-AE04C04E5E46Q33638344-79BC605B-E854-4528-A557-0D018202F003Q33654894-968A55B3-215F-4225-8E51-15B71836265BQ33745075-85551D56-F4E3-4A40-8D86-12BC27B819B2Q33747277-2E39B20F-2C0E-4331-9735-AEA2D7C32031Q33754603-8C23987B-D38B-4CEC-8FA2-46693A9F9281Q33785927-6DE08121-BDE6-422B-B894-04ADF2135423Q33921067-48E83F8E-F9A8-41C1-B3A7-2DF3DD17C724Q34005579-EC3447A6-C8F7-4DEB-ABDD-91523D0380E2Q34031293-E093B827-BAF2-45E4-A501-544EF7652E51Q34100838-078F4714-3BB1-4C60-897A-C26E8F20A16CQ34109861-CF4A3B7E-D253-4296-BBF1-3A52C47F9045Q34121339-88758F19-DA5B-4D15-BE1E-65CD10B847D3Q34293285-D3511127-5BDA-47EB-9C27-4EECEF6AB618Q34317299-7CDBB3CA-E10A-4EEE-BF79-79C9A1EB0AC4Q34335004-1E691965-5B7A-4C61-9263-1E84D7D970D3Q34432431-08C72C91-8CCD-4417-9FA7-1D2B49C31B4AQ34572894-6F813495-89E3-4096-B2EC-B13412B92518Q34578418-87A46A9F-2C63-4AB3-B7E7-9E3634569C38Q34635424-0D8B24F8-724E-40FA-835A-48D5D0E977E1Q34641211-882629B7-455E-4115-BA8C-B272CD2E7EE0Q34683348-DBD4A7EB-6849-4376-A54D-FC8CD3561EDEQ34804754-BABEFBD5-EC96-4775-BCF2-054EAA733C4CQ35051746-300D9A50-E37A-4BE7-8BC1-43CD08E32FCCQ35060248-67234FBF-91D9-4CDE-8C89-833D1A04A122Q35144330-6BE0D0E0-0FE6-42A0-A7B5-B516D4C71E68Q35252470-680D86C6-811C-4AC5-9B06-C42FB9CFAE47Q35538367-7480EB78-78A9-4664-85D2-9972F7F4C747
P2860
Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Dasatinib (BMS-354825), a dual ...... iated with human malignancies.
@en
Dasatinib (BMS-354825), a dual ...... iated with human malignancies.
@nl
type
label
Dasatinib (BMS-354825), a dual ...... iated with human malignancies.
@en
Dasatinib (BMS-354825), a dual ...... iated with human malignancies.
@nl
prefLabel
Dasatinib (BMS-354825), a dual ...... iated with human malignancies.
@en
Dasatinib (BMS-354825), a dual ...... iated with human malignancies.
@nl
P2093
P1433
P1476
Dasatinib (BMS-354825), a dual ...... iated with human malignancies.
@en
P2093
Amie S Corbin
Arin Schroeder
Carsten Bokemeyer
Diana Griffith
Francis Y Lee
Marcus M Schittenhelm
Michael W N Deininger
Sharon Shiraga
P304
P356
10.1158/0008-5472.CAN-05-2050
P407
P577
2006-01-01T00:00:00Z